Considering the significance of comorbidities in the progression of HFpEF, the latest European Society of Cardiology (ESC) HF management guidelines [5] recommend the active screening and treatment of comorbidities as a cornerstone of therapy for patients with this type of heart failure, alongside treatment with a sodium-glucose cotransporter 2 (SGLT2) inhibitor and management of the congestive syndrome. This evidence concerns the gene SLC5A2 and heart failure.